Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 14, 2011

Chimerix Pockets $45M to Further Antiviral Development

  • Chimerix completed a $45 million Series F financing round. Proceeds will be used to support the development of two clinical-stage candidates, CMX001 and CMX157.

    CMX001 is a broad-spectrum antiviral that is being tested as a treatment for life-threatening viral infections in immunocompromised patients. It also has potential as a countermeasure in the event of a smallpox release, according to Chimerix. CMX157 is a nucleoside analogue in development for the treatment of HIV infections including those caused by multidrug-resistant viruses.

    CMX001 is in a Phase II study of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients. A Phase II trial of the compound in pediatric and adult hematopoietic stem cell transplant patients with adenovirus-related diseases is currently being initiated, says Chimerix. The smallpox trials have received federal funding from the NIAID, according to the company.

    The firm is also conducting an open-label study with CMX001 under expanded access protocol for the treatment of critically ill patients with any of 12 different double-stranded DNA viral infections. These include AdV, herpes viruses (such as CMV, herpes simplex virus, and Epstein Barr virus), polyoma viruses such as BK virus and JC virus, and pox viruses. Chimerix says that the trial builds on its experience working with clinicians at over 55 leading institutions in the U.S., Canada, Europe, and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under emergency INDs.

    The firm recently completed a Phase I study of CMX157. The study demonstrated that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »